Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,241 to 3,260 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Left Atrial Ablation vs Rate or Rhythm Control Therapy: Number of Participants With Cardiovascular Hospitalization | 556 of 1,108 605 of 1,096 | -5.0 points -9.2 to -0.9 | 2,204 | NCT00911508 Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial |
| Left Atrial Ablation vs Rate or Rhythm Control Therapy: deaths from any cause | 58 of 1,108 67 of 1,096 | -0.9 points -2.8 to 1.1 | 2,204 | NCT00911508 Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial |
| Left Atrial Ablation vs Rate or Rhythm Control Therapy: Number of Participants With Cardiovascular Death or Disabling Stroke | 24 of 1,108 27 of 1,096 | -0.3 points -1.6 to 1.0 | 2,204 | NCT00911508 Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial |
| Left Atrial Ablation vs Rate or Rhythm Control Therapy: serious adverse events | 454 of 1,108 430 of 1,096 | 1.7 points -2.3 to 5.8 | 2,204 | NCT00911508 Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial |
| On Pump vs Off Pump: Short-term End Point | 61 of 1,099 77 of 1,104 | -1.4 points -3.5 to 0.6 | 2,203 | NCT00032630 Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass |
| On Pump vs Off Pump: serious adverse events | 201 of 1,099 220 of 1,104 | -1.6 points -4.9 to 1.6 | 2,203 | NCT00032630 Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass |
| On-Pump vs Off-Pump: deaths from any cause | 131 of 1,099 168 of 1,104 | -3.3 points -6.2 to -0.4 | 2,203 | NCT01924442 ROOBY Trial Follow-up Extension |
| On-Pump vs Off-Pump: serious adverse events | 426 of 1,099 496 of 1,104 | -6.2 points -10.3 to -2.0 | 2,203 | NCT01924442 ROOBY Trial Follow-up Extension |
| Percutaneous Coronary Intervention Group vs Medical Therapy Group: Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF) | 230 of 1,101 219 of 1,100 | 1.0 points -2.4 to 4.3 | 2,201 | NCT00004562 Occluded Artery Trial (OAT) |
| Percutaneous Coronary Intervention Group vs Medical Therapy Group: serious adverse events | 226 of 1,101 227 of 1,100 | -0.1 points -3.5 to 3.3 | 2,201 | NCT00004562 Occluded Artery Trial (OAT) |
| Pharmacist Intervention vs Control - Usual Care: Number of Participants With PTH Measurement During the Study Period | 502 of 1,070 182 of 1,129 | 30.8 points 27.1 to 34.4 | 2,199 | NCT01290614 A Chronic Care Model Based Quality Improvement (QI) Program to Improve the Care of Patients With Chronic Kidney Disease (CKD) |
| Chemotherapy vs Atezolizumab and Chemotherapy: deaths from any cause | 58 of 1,098 72 of 1,101 | -1.3 points -3.3 to 0.7 | 2,199 | NCT03498716 A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer |
| Intervention vs Control: Prevalence of Hypothermia at 24 Hours Post-randomisation | 448 of 1,096 585 of 1,101 | -12.3 points -16.4 to -8.1 | 2,197 | NCT02811432 Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa |
| Intervention Arm vs Control Arm: Patient Survival- Percentage of Patients That Died During Study | 195 of 1,300 144 of 896 | -1.1 points -4.2 to 2.0 | 2,196 | NCT03860818 Improving Transplant Medication Safety Through A Technology and Pharmacist Intervention |
| Intervention Arm vs Control Arm: Number of Participants With Graft Survival | 1,255 of 1,300 864 of 896 | 0.1 points -1.4 to 1.8 | 2,196 | NCT03860818 Improving Transplant Medication Safety Through A Technology and Pharmacist Intervention |
| Intervention Arm vs Control Arm: deaths from any cause | 195 of 1,300 144 of 896 | -1.1 points -4.2 to 2.0 | 2,196 | NCT03860818 Improving Transplant Medication Safety Through A Technology and Pharmacist Intervention |
| Intervention Arm vs Control Arm: serious adverse events | 436 of 1,300 412 of 896 | -12.4 points -16.6 to -8.3 | 2,196 | NCT03860818 Improving Transplant Medication Safety Through A Technology and Pharmacist Intervention |
| Nirsevimab vs No Intervention: Number of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization From Days 366 to 731 Post-dosing/Randomization (for United Kingdom Reconsented Participants) | 7 of 1,132 2 of 1,062 | 0.4 points -0.2 to 1.1 | 2,194 | NCT05437510 Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life |
| Bivalirudin vs Standard of Care: Heparins With Optional GPI: serious adverse events | 145 of 1,099 129 of 1,094 | 1.4 points -1.4 to 4.2 | 2,193 | NCT01087723 European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial |
| Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: Number of Participants With Human Immuno Deficiency Virus-1 (HIV-1) Infection Diagnosed Between Month 7 to Month 24 Post Enrollment | 54 of 1,080 65 of 1,108 | -0.9 points -2.8 to 1.1 | 2,188 | NCT03060629 A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa |
Code
curl "https://conductscience.org/api/comparisons/v1?page=163"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=163
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00911508-cf0db215",
"title": "Left Atrial Ablation vs Rate or Rhythm Control Therapy: Number of Participants With Cardiovascular Hospitalization",
"summary": "556 of 1108 against 605 of 1096; risk difference -5.0 points, 95% interval -9.2 to -0.9; NCT00911508, Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial",
"record": "/library/comparisons/NCT00911508-cf0db215",
"nct_id": "NCT00911508",
"kind": "outcome",
"participants": 2204,
"risk_difference": {
"value": -0.050202245118448396,
"lower": -0.09164186705801602,
"upper": -0.008514553663830783
},
"group_1": "556 of 1,108",
"group_2": "605 of 1,096",
"difference": "-5.0 points",
"interval": "-9.2 to -0.9",
"trial_title": "Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial"
},
{
"id": "NCT00911508-deaths",
"title": "Left Atrial Ablation vs Rate or Rhythm Control Therapy: deaths from any cause",
"summary": "58 of 1108 against 67 of 1096; risk difference -0.9 points, 95% interval -2.8 to 1.1; NCT00911508, Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial",
"record": "/library/comparisons/NCT00911508-deaths",
"nct_id": "NCT00911508",
"kind": "deaths",
"participants": 2204,
"risk_difference": {
"value": -0.008784816464201955,
"lower": -0.028386354506702044,
"upper": 0.010669185835948884
},
"group_1": "58 of 1,108",
"group_2": "67 of 1,096",
"difference": "-0.9 points",
"interval": "-2.8 to 1.1",
"trial_title": "Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=164",
"request_id": "_L1vcw-pcWVtByL9"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant